GSK to provide additional 180 million doses of pneumococcal vaccine to GAVI over the next 12 years

    GSK said it will provide an additional 180 million doses of its Synflorix pneumococcal vaccine to GAVI over the next 12 years to help expand immunisation programmes against pneumococcal disease to 72 developing countries by 2023. The actionbuilds on the 300 million doses that GSK committed to GAVI in March 2010 through an innovative financing mechanism known as the Advance Market Commitment (AMC). In total, up to 160 million children in developing countries could now be protected with Synflorix against pneumococcal disease by 2023.”

GSK noted that it is providing the additional 180 million doses of Synflorix to GAVI “at a small fraction of developed world prices.”

http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-815404.htm